Specialist Updates 
Respiratory

First-in-class drug for chronic cough shows efficacy

Only the higher dose gave better results than placebo in two parallel phase three trials, investigators report
Medicom Staff writer
0
10 September 2020
Save
ClosePlease login

AusDoc brings you the latest news from the European Respiratory Society Congress 2020.

Gefapixant, a first-in-class P2X3 receptor antagonist, is efficacious for chronic cough but only at the higher of two doses tested, trial results show.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .